Date: 2014-07-24
Type of information: Development agreement
Compound:
Company: Merck Serono (Germany) Institute of Experimental Neurology (INSPE) of San Raffaele University and Research Hospital (Italy)
Therapeutic area: Neurodegenerative diseases
Type agreement: collaboration development
Action mechanism:
Disease: neurological diseases such as multiple sclerosis
Details: * On July 23, 2014, Merck Serono, the biopharmaceutical division of Merck KGaA, and the Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research Hospital, announced the continuation of a strategic alliance to develop pre-clinical and clinical research projects in the field of neurodegenerative diseases. The research will focus on developing innovative therapies against serious and disabling neurological diseases affecting young adults in particular, such as multiple sclerosis. Established in 2004, the renewal of the partnership extends the agreement between the parties for two additional years. San Raffaele University and Research Hospital will provide its know-how and its laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.
Financial terms:
Latest news:
